Abstract:Highlights • Intracellular ROS kinetics dictates antigen-presenting mode. • Sustained TLR2 activation triggers intracellular ROS kinetics required for cross-presentation. • A scaffold vaccine enabling "retention-and-release" for sustained TLR2 activation in DCs promotes cross-presentation. • The scaffold vaccine induces robust, CD8 + T cells-mediated anti-tumor immune responses in Apc min/+ transgenic mice. Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8 + cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8 + T cells – a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection. This vaccine comprises polysaccharide frameworks that "hook" TLR2 agonist (acGM) via tunable hydrophobic interactions and forms a 3D macroporous scaffold via click chemistry upon subcutaneous injection. Its retention-and-release of acGM enables sustained TLR2 activation in abundantly recruited dendritic cells in situ , inducing intracellular production of reactive oxygen species (ROS) in optimal kinetics that crucially promotes efficient antigen cross-presentation. The scaffold loaded with model antigen ovalbumin (OVA) or tumor specific antigen can generate potent immune responses against lung metastasis in B16-OVA-innoculated wild-type mice or spontaneous colorectal cancer in transgenic Apc Min/+ mice, respectively. Notably, it requires neither additional adjuvants nor external stimulation to function and can be adjusted to accommodate different antigens. The developed scaffold vaccine may represent a new, competent tool for next-generation personalized cancer vaccination. Graphical abstract A scaffold vaccine that promotes antigen cross-presentation to trigger CD8 + T cell-mediated anti-tumor immune responses . In this study, we discover that the kinetics of intracellular ROS, unexpectedly, dictates the mode of antigen presentation. Persistent production in moderate dose promotes antigen cross-presentation. To create optimal intracellular ROS kinetics for lysosomal disruption and antigen escape, we design a 3D injectable scaffold for the "retention-and-release" of a TLR2 agonist glycan upon subcutaneous implantation. Installation of tunable hydrophobic interactions between the scaffold and the "hooked" agonist enables sustained TLR activation in the abundantly recruited DCs in situ , which triggers consequently efficient cross-presentation of tumor antigens. The efficacy of this novel scaffold vaccine is subsequently undergoing comprehensive evaluations in both wild-type and transgenic mice against localized, metastatic, and spontaneous tumors. Download : Download high-res image (369KB) Download : Download full-size image

T Cell Activating Thermostable Self-Assembly Nanoscaffold Tailored for Cellular Immunity Antigen Delivery

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Asymmetric Assembly and Self-Adjuvanted Antigen Delivery Platform for Improved Antigen Uptake and Antitumor Effect

Rapid and efficient immune response induced by a designed modular cholera toxin B subunit (CTB)-based self-assembling nanoparticle

Abstract 499: Enhancing neoantigen cancer vaccine efficacy with a self-assembling peptide conjugates nanoparticle platform

Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine

Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy

An Aluminum Adjuvant-Integrated Nano-Mof As Antigen Delivery System to Induce Strong Humoral and Cellular Immune Responses

A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production

Self-Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design

Codelivery of Nod2 and Tlr9 Ligands Via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

Design and Optimization of a Novel Proteomimetic Polymer Nanoplatform for the Co-delivery of Antigens with Adjuvants

Antigen-specific T Cell Activation Through Targeted Delivery of In-Situ Generated Antigen and Calcium Ionophore to Enhance Antitumor Immunotherapy.

A General Strategy toward Self-assembled Nanovaccine Based on Cationic Lentinan to Induce Potent Humoral and Cellular Immune Responses

Virus Envelope-Like Self-Assembled Nanoparticles Based on Α-Cd/peg for Antigens Targeting to Dendritic Cells.

An antigen self-assembled and dendritic cell-targeted nanovaccine for enhanced immunity against cancer

Precise Assembly of Multiple Antigens on Nanoparticles with Specially Designed Affinity Peptides

Clickable amino acid derivative tuned self-assembly of antigen and adjuvant for cancer immunotherapy

Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity